Akèy › Kansè Metastatik › Arizona › Scottsdale
Etid klinik pou Kansè Metastatik nan Scottsdale, AZ
17 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Scottsdale (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors
Ap rekrite
- Mayo Clinic in Arizona, Scottsdale
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Ap rekriteFaz 2
- Mayo Clinic in Arizona, Scottsdale
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Mayo Clinic, Scottsdale
- Ironwood Cancer & Research Centers, Scottsdale
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Ironwood Cancer & Research Centers, Scottsdale
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Ap rekriteFaz 1/2
- Mayo Clinic Arizona, Scottsdale
A Study of KK2269 in Adult Participants With Solid Tumors
Ap rekriteFaz 1
- Mayo Clinic Arizona, Scottsdale
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Ap rekriteFaz 2
- Research Site, Scottsdale
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Honor Health, Scottsdale
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic (Arizona), Scottsdale
A Study of PYX-201 in Advanced Solid Tumors
Ap rekriteFaz 1
- HonorHealth Research Institute, Scottsdale
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Scottsdale
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- HonorHealth Research Insisute, Scottsdale
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- HonorHealth Research Institute, Scottsdale
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Ap rekriteFaz 1
- Honor Health Research Institute, Scottsdale
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 1/2
- Honor Health Resarch Institute, Scottsdale
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Scottsdale
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Ap rekriteFaz 1/2
- Mayo Clinic in Arizona, Scottsdale
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Scottsdale
- Kansè nan tete18 etid
- Kansè (tout kalite)18 etid
- Kansè pwostat17 etid
- Kansè kolorektal16 etid
- Kansè Poumon ki pa ti selil15 etid
- Kansè pankreyas13 etid
- Melanom10 etid
- Kolit Ulseratif8 etid
- Kansè poumon8 etid
- Kansè fwa (Kasinòm epatoselilè)7 etid
- Maladi Alzheimer7 etid
- Kansè tete negatif triple7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.